09 July 2019 | News
Powered by GenomOncology's Precision Oncology Platform, the site offers clinicians, researchers and patients access to a wealth of information about the latest developments in precision cancer medicine
Image Courtesy: prnewswire
Vanderbilt-Ingram Cancer Center and GenomOncology LLC announce the launch of the newly redesigned and improved My Cancer Genome website. The new site showcases the breadth and depth of curated content from My Cancer Genome.
Powered by GenomOncology's Precision Oncology Platform, the site offers clinicians, researchers and patients access to a wealth of information about the latest developments in precision cancer medicine. Using powerful search and filtering technology, users can explore clinical trials, biomarkers, diseases, drugs or pathways. My Cancer Genome ties together the body of knowledge on precision cancer medicine.
The improvements with www.mycancergenome.org include:
"Ever since the release of the first version of My Cancer Genome, we have been envisioning an updated version that enables us to scale and expand our content. This release realizes the vision of that long-term goal and enhances the website's features to drive precision cancer medicine treatment”, said Mia Levy, M.D., PhD Levy co-founded My Cancer Genome, the nation's first web-based precision cancer knowledge resource, in 2011.
"Our goal in creating this new website was to retain the focus on what clinicians, researchers, and patients need and want out of a precision oncology website, while at the same time greatly expanding the content. We are also very excited to present our much improved clinical trial search tool," said Christine Micheel, Ph.D., co-lead of My Cancer Genome.
"The new My Cancer Genome site is designed for flexibility and adaptability, providing both curated and calculated content to physicians, researchers and patients. This tool will allow those practising in oncology or affected by cancer the ability to find and apply real-time content. We are excited to partner with Vanderbilt and the My Cancer Genome team to bring this new capability to market", said Brad Wertz, CEO of GenomOncology
To develop the new website, the My Cancer Genome team worked with development partner and content licensee GenomOncology. Additional features of My Cancer Genome will continue to be rolled out in a series of releases as the next phase of the website is completed. For more information on My Cancer Genome, visit www.mycancergenome.org.